Grace Therapeutics (GRCE) versus Its Peers Head-To-Head Contrast

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Grace Therapeutics to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Grace Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8411	22254	50400	1349	2.54

Grace Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 500.00%. As a group, “Pharmaceutical preparations” companies have a potential upside of 252.08%. Given Grace Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Grace Therapeutics is more favorable than its competitors.

Valuation & Earnings

This table compares Grace Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.72
Grace Therapeutics Competitors	$9.89 billion	$136.37 million	-3.96

Grace Therapeutics’ competitors have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Grace Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ competitors have a beta of 3.86, indicating that their average stock price is 286% more volatile than the S&P 500.

Profitability

This table compares Grace Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Insider and Institutional Ownership

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.5% of Grace Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Grace Therapeutics beats its competitors on 7 of the 13 factors compared.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.